Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer

Inclusion Criteria:

• Signed informed consent must be obtained prior to performing any specificpre-screening and screening procedure

• Male or female >= 18 years of age at the time of informed consent

• Histologically or cytologically confirmed diagnosis of advanced/metastaticdifferentiated thyroid cancer

• Radio active iodine refractory disease

• BRAFV600E mutation positive tumor sample as per Novartis designated centrallaboratory result

• Has progressed on at least 1 but not more than 2 prior VEGFR targeted therapy

• Eastern Cooperative Oncology Group performance status >= 2

• At least one measurable lesion as defined by RECIST 1.1

Exclusion Criteria:

• Anaplastic or medullary carcinoma of the Tyroid

• Previous treatment with BRAF inhibitor and/or MEK inhibitor

• Concomitant RET Fusion Positive Thyroid cancer

• Receipt of any type of small molecule kinase inhibitor within 2 weeks beforerandomization

• Receipt of any type of cancer antibody or systemic chemotherapy within 4 weeksbefore randomization

• Receipt of radiation therapy for bone metastasis within 2 weeks or any otherradiation therapy within 4 weeks before randomization

• A history or current evidence/risk of retinal vein occlusion or central serousretinopathy